Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

NCT04848064 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Adult T-Cell Leukemia/Lymphoma
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Refractory Adult T-Cell Leukemia/Lymphoma
Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
BIOLOGICAL: Mogamulizumab
BIOLOGICAL: Natural Killer Cell Therapy
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration

Sponsor

John Reneau